NanoVibronix Inc (NASDAQ: NAOV) announced on Monday the successful completion of the pilot phase of a randomised controlled trial for UroShield, conducted by researchers at the University of Michigan.
This initial phase focused on nursing home residents and evaluated UroShield's ability to enhance patient quality of life by reducing urinary tract infections, catheter blockages and pain linked to long-term catheter use.
The study is set to progress to a full trial in 2025, building on the outcomes of the pilot phase.
UroShield employs NanoVibronix's patented low-intensity Surface Acoustic Wave (SAW) technology, designed to disrupt biofilms, reduce bacterial colonisation and alleviate pain.
Headquartered in Tyler, Texas, with R&D operations in Nesher, Israel, NanoVibronix specialises in portable therapeutic devices, including PainShield and WoundShield, which enable treatment without continuous medical supervision.
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission